Last update: March 23, 2018

Κετιριζίνη υδροχλωρική

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

A second generation antihistamine, derived from piperazine and hydroxyzine metabolite, with minimal sedative effects and very low toxicity even at high doses.

No problems were detected in the short or long term in an infant whose mother took it during the first month after delivery as part of the treatment for pemphigus (Westermann 2012).

Its high binding to plasma proteins makes its transfer to milk very unlikely.

The British Society for Allergy and Clinical Immunology and other experts consider it safe during breastfeeding (Butler 2014, Powell 2007).

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Κετιριζίνη υδροχλωρική is Cetirizine Hydrochloride in Greek.

Is written in other languages:

Κετιριζίνη υδροχλωρική is also known as

Group

Κετιριζίνη υδροχλωρική belongs to this group or family:

Tradenames

Main tradenames from several countries containing Κετιριζίνη υδροχλωρική in its composition:

List of 11 tradenames
  • Alerlisin™
  • Coulergin™
  • Reactine (Italy)™. Contains other elements than Κετιριζίνη υδροχλωρική in its composition
  • Reactine™
  • Reactine Duo™. Contains other elements than Κετιριζίνη υδροχλωρική in its composition
  • Reactine Plus™. Contains other elements than Κετιριζίνη υδροχλωρική in its composition
  • Stopcold™. Contains other elements than Κετιριζίνη υδροχλωρική in its composition
  • Virlix™
  • Zirtec™
  • Zyrlex™
  • Zyrtec™

Pharmacokinetics

Variable Value Unit
Bioavailability 70 %
Molecular weight 462 daltons
Protein Binding 93 %
VD 0,56 l/Kg
pKa 3,36 -
Tmax 1 - 2,2 hours
T1/2 8,3 hours

References

  1. Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014 Mar;70(3):417.e1-10; quiz 427. Abstract
  2. Westermann L, Hügel R, Meier M, Weichenthal M, Zillikens D, Gläser R, Schmidt E. Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol. 2012 Abstract
  3. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM; British Society for Allergy and Clinical Immunology (BSACI). BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007 Abstract Full text (link to original source) Full text (in our servers)

Total visits

1,378

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM